Current Cancer Drug Targets

Editor-in-Chief:

Ruiwen Zhang
Center for Drug Discovery
University of Houston
3455 Cullen Blvd.
Houston, TX 77204
USA

Back

Become EABM
Become Reviewer

Articles Ahead of Print

Withdrawal Notice: Novel Homeodomain Transcription Factor Nkx2.2 in the Brain Tumor Development

Volume:18
Mubeena PM Mariyath, Mehdi Hayat Shahi*, Shirin Farheen, Mohd Tayyab, Nabeela Khanam and Asif Ali

Fas Ligand Enhances Apoptosis of Human Lung Cancer Cells Cotreated with RIG-I-Like Receptor Agonist and Radiation

Volume:20
Yoshiaki Sato, Hironori Yoshino*, Eichi Tsuruga and Ikuo Kashiwakura

Hypermethylation of Single CpG Dinucleotides at the Promoter of CXCL13 Gene Promoting Cell Migration in Cervical Cancer

Volume:20
Dong Ma , Shao-Bei Fan , Na Hua, Guo-Hua Li, Quan Chang and Xiao Liu *

Idronoxil as an Anticancer Agent: Activity and Mechanisms

Volume:20
Kate Porter*, W. Douglas Fairlie, Olivier Laczka, Frederic Delebecque and John Wilkinson

Disintegrin Tablysin-15 Suppresses Cancer Hallmarks in Melanoma Cells by Blocking FAK/Akt/ERK and NF-κB Signaling

Volume:20
Zhenhui Deng, Qingye Zeng, Jinwei Chai, Bei Zhang, Wenhong Zheng, Xueqing Xu and Jiguo Wu*

Old and New Approaches to Target the Hsp90 Chaperone

Volume:19
Jackee Sanchez, Trever R. Carter, Mark S. Cohen* and Brian S. Blagg

circEPSTI1 Acts as a ceRNA to Regulate the Progression of Osteosarcoma

Volume:19
Xinyu Tan, Duxun Tan, Haomiao Li, Ye Lin, Zhishen Wen and Canjun Zeng*

Withdrawn: The Structural Bioinformatics Analysis of Biophenolic Lignan- Estrogen Receptor Interaction

Volume:17
Farzaneh Mohamadyar-Toupkanlou*, Mina Esfandiari, Mahshid Sadat Kashef-Saberi, Mahboubeh Kabiri Renani and Masoud Soleimani